.jpg)
.png)
Member Spotlight
This page was last updated: Aug 24, 2018
Background
Article By:
GEORGE S. ABELA, MD, MSc, MBA
Professor and Chief, Division of Cardiology
Michigan State University
East Lansing, MI
Volanesorsen is a novel pharmacotherapy designed to treat patients with Familial Chylomicronemia Syndrome (FCS). This is a highly comorbid disease without any currently available pharmacotherapies to help reduce triglycerides or the more feared complication, pancreatitis. This has left a void in treatment that volanesorsen has attempted to address.
Article By:
DAVID J. DAVIDSON, MD
Clinical Educator
NorthShore Medical Group
Chicago, IL
Diplomate, American Board of Clinical Lipidology
COMMITTEE NOTE TO MEMBERS OF THE NATIONAL LIPID ASSOCIATION: At the request of the NLA President, the NLA Board of Directors, the Science and Policy Council, the Practice Management Council and the Health Quality and Research Committee, it is with pleasure that the 2017-18 NLA Therapeutics Committee presents a Special Report on how to best incorporate PCSK9 Inhibitors into routine clinical lipid practice by integrating best available evidence into the routine process of care.
Article By:
DEAN A. BRAMLET, MD, FNLA
2017-18 Co-Chair, NLA Therapeutics Committee
Assistant Consulting Professor of Medicine
Duke University
Medical Director, Cardiovascular Diagnostic Center
The Heart & Lipid Institute of Florida
St. Petersburg, FL
Diplomate, American Board of Clinical Lipidology
DAVID R. NEFF, DO
2017-18 Co-Chair, NLA Therapeutics Committee
President, Midwest Lipid Association
Michigan State University
College of Osteopathic Medicine
Associate Clinical Professor
Department of Family & Community Medicine
Ingham Regional Medical Center
Lansing, MI
DEAN G. KARALIS, MD, FNLA
Clinical Professor of Medicine
Jefferson University Hospital
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
PAUL E. ZIAJKA, MD, PhD, FNLA
Director
Florida Lipid Institute
Winter Park, FL
Diplomate, American Board of Clinical Lipidology
Lipodystrophies are a group of disorders of fat tissue loss that are classified according to whether the condition is genetic or acquired and by the distribution of fat loss, either generalized or partial (Table 1).1 Generalized lipodystrophy is a rare, complex, and clinically heterogeneous disorder characterized by the widespread loss of adipose tissue.
Article By:
JONATHAN Q. PURNELL, MD
Professor of Medicine, Division of Cardiovascular Medicine School of Medicine
Graduate Programs in Human Nutrition School of Medicine
Oregon Health & Science University
Portland, OR
ELIOT A. BRINTON, MD, FNLA
President, Utah Lipid Center
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology
SERGIO FAZIO, MD, PhD, FNLA
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
DAVID R. NEFF, DO
President, Midwest Lipid Association
Michigan State University
College of Osteopathic Medicine
Associate Clinical Professor
Department of Family & Community Medicine
Ingham Regional Medical Center
Lansing, MI
What is the Structure of Lp(a)?
Article By:
PATRICK M. MORIARTY, MD, FNLA
Professor of Medicine
Director of Clinical Pharmacology
University of Kansas Medical Center
Kansas City, KS
MICHAEL B. BOFFA, PhD
Associate Professor
Department of Biochemistry
Schulich School of Medicine & Dentistry
The University of Western Ontario
London, ON
MARLYS KOSCHINSKY, PhD, FNLA
Scientific & Executive Director, Robarts Research Institute
Professor, Department of Physiology & Pharmacology
Schulich School of Medicine & Dentistry
The University of Western Ontario
London, ON
Our healthcare organization has designated “population health management” as a core part of our strategy planning and accountability. This is reflected through the implementation of what is defined as the “quadruple aim:”
–providing health care which is affordable, improves the patient experience from the standpoint of quality and satisfaction in terms of outcomes, and also supports the physicians and providers of that healthcare in their life goals and personal quality–
Article By:
KAYE-EILEEN WILLARD, MD, FNLA
Co-Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology
Greetings from those of us at the Midwest Lipid Association (MWLA). We all trust that you had an excellent summer as we head into cooler weather and color changes up here in the Midwest and Canada. For those of you who do not know, our Canadian partners who are National Lipid Association (NLA) members are represented through the MWLA Chapter. It’s our pleasure to bring you this issue of LipidSpin.
Article By:
DAVID R. NEFF, DO
President, Midwest Lipid Association
Michigan State University
College of Osteopathic Medicine
Associate Clinical Professor
Department of Family & Community Medicine
Ingham Regional Medical Center
Lansing, MI
The National Lipid Association has been quite busy since the 2018 Scientific Sessions in Las Vegas. Below are some of the recent highlights. Stay tuned for more recurring updates from our organization.
Article By:
ALAN S. BROWN, MD, FNLA
President, National Lipid Association
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology
Last Updated: Wednesday, 12-Sep-2018 18:30:00 EDT
W. Virgil Brown, MD, FNLA and Ernst J. Schaefer, MD, FNLA, chairs of the Donald S. Fredrickson Conferences and Webinars on Familial Lipoprotein Disorders, are accepting case submissions for an upcoming webinar.
The deadline for submissions is Sunday, September 30. If a case is selected, the case submitter will be paired with one or several experts who will help them present and dissect your case in front of a live audience. The webinars will take place quarterly, and submissions may be considered for future webinars.